Into thoroughly implement the Several Measures to Bail Enterprises Out in the Drug Regulatory Field by Tibet Autonomous Region Medical Products Administration and provide relevant comments on "one-to-one" policy consultation and technical guidance for pharmaceutical enterprises in Tibet Autonomous Region, upon application by Tibet Pharmaceutical, the Tibet Autonomous Region Medical Products Administration organized relevant divisions and offices to conduct online exchanges with Tibet Pharmaceutical on four topics involving drug production license, registration and circulation on December 29, 2022. The meeting was presided over by Wu Yinan, a member of the Leading Party Group and Deputy Director of the Tibet Autonomous Region Medical Products Administration, with the Registry Office, Drug Supervision Office, Tibetan Medicine Evaluation and Certification Center of the Tibet Autonomous Region Medical Products Administration, Tang Bo, Deputy General Manager of the Company, and registration and quality-related personnel of the Production Management Center as the attendees. The leaders from relevant divisions, offices and centers of the Tibet Autonomous Region Medical Products Administration answered the four issues one by one from laws, regulations and policies to practical operations.

Before the end of the meeting, Deputy Director Wu Yinan highly recognized the Companys proactive approach in addressing issues, active communication and candid exchanges, and praised the Company for its long-term participation in social welfare undertakings such as Disaster Relief and Epidemic Prevention, 10,000 Enterprises Help 10,000 Villages, and Healthy China Initiative, and its commitment to enriching border areas and developing Tibet. At the same time, Deputy Director Wu Yinan, on behalf of the Tibet Medical Products Administration, said that she would vigorously support the development of drug manufacturers in the autonomous region, actively carry out the Help Enterprises Bail Out, assist enterprises in establishing smooth communication channels, grasp policy orientation and promote high-quality development of the pharmaceutical industry in the region.